May 7 |
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
|
May 6 |
Madrigal Pharmaceuticals Q1 2024 Earnings Preview
|
Apr 30 |
Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
|
Apr 24 |
Madrigal Statement on the Passing of Dr. Stephen Harrison
|
Apr 24 |
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
|
Apr 23 |
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
|
Apr 15 |
Latest Insider Selling in April 2024: 10 Stocks to Watch
|
Apr 9 |
Madrigal announces US launch of NASH/MASH drug Rezdiffra
|
Apr 9 |
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
|
Apr 5 |
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
|